Article

Segment 7: Guidelines for Diagnostic Test Use

The panelists discuss guidelines for diagnostic test use and the biggest challenge from a payer standpoint.

Francisco J. Esteva, MD, PhD, and Daniel F. Hayes, MD, discuss guidelines for diagnostic test use from the National Comprehensive Cancer Network and the American Society of Clinical Oncology and the differences in how each organization approached the development of guidelines.

John L. Fox, MD, added that the biggest challenges with guidelines are the underuse and overuse of diagnostics—the former being a larger issue than the latter. From a payer vantage, tests that are well validated and have clinical utility should be done and they are willing to pay because the high cost of patients receiving an inappropriate therapy is an avoidable expense.

“So we’re encouraging testing and making sure that patients are appropriate for therapy,” he said.

Related Videos
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Cathy Eng, MD, FACP, FASCO
Leigh Maria Ramos-Platt, MD
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Molly Dean, MSW, Siftwell
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo